Lineage Cell Therapeutics (LCTX) Reports In-Line Q3 EPS

Lineage Cell Therapeutics (NYSE: LCTX) reported Q3 EPS of ($0.05), in-line with the analyst estimate of ($0.05). Revenue for the quarter came in at $2.27 million versus the consensus estimate of $510 thousand.

For earnings history and earnings-related data on Lineage Cell Therapeutics (LCTX) click here.

You May Also Be Interested In

• Home Depot beats estimates, reaffirms fiscal 2026 guidance
• uCloudlink Group Inc. (UCL) Misses Q2 EPS by 1c ; Offers Guidance
• Home Depot (HD) Tops Q2 EPS by 19c, reaffirms guidance